# An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

> **NCT01588184** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 95 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01588184
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-13
- **Primary completion:** 2019-09-27
- **Final completion:** 2019-09-27
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2020-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01588184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01588184, "An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01588184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*